These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28845514)

  • 41. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
    Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
    Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
    Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
    Civantos F
    Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
    Yee DS; Lowrance WT; Eastham JA; Maschino AC; Cronin AM; Rabbani F
    BJU Int; 2010 Jan; 105(2):185-90. PubMed ID: 19594741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
    Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T
    Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical therapy of prostate cancer. A review.
    Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
    Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
    Lawton CA; DeSilvio M; Roach M; Uhl V; Kirsch R; Seider M; Rotman M; Jones C; Asbell S; Valicenti R; Hahn S; Thomas CR
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):646-55. PubMed ID: 17531401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significance of neoadjuvant hormonal therapy in radical retropubic prostatectomy: a retrospective single-surgeon study.
    Yamamichi F; Shigemura K; Morishita S; Yamanaka K; Tanaka K; Miyake H; Fujisawa M
    Yonsei Med J; 2013 Mar; 54(2):410-5. PubMed ID: 23364975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant Approaches Prior To Radical Prostatectomy.
    Ryan ST; Patel DN; Parsons JK; McKay RR
    Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of the tumor volume in radical prostatectomy specimens after neoadjuvant hormonal therapy.
    Miyake H; Sakai I; Harada K; Takechi Y; Hara I; Eto H
    Urol Int; 2005; 74(1):27-31. PubMed ID: 15711105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.
    Selli C; Montironi R; Bono A; Pagano F; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Mazzucchelli R; Santinelli A;
    J Clin Pathol; 2002 Jul; 55(7):508-13. PubMed ID: 12101195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
    Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
    Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgen deprivation therapy improves pneumoperitoneum time during laparoscopic radical prostatectomy in Japanese patients with enlarged prostates.
    Takeda T; Miyajima A; Kaneko G; Kikuchi E; Nakagawa K; Oya M
    Asian J Endosc Surg; 2014 May; 7(2):145-51. PubMed ID: 24423024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
    Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
    Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer.
    Yuno T; Miyata Y; Matsuo T; Mukae Y; Otsubo A; Mitsunari K; Ohba K; Suda T; Saito S; Sakai H
    Anticancer Res; 2020 Oct; 40(10):5567-5575. PubMed ID: 32988880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
    Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
    Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.